Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Common Equity (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Common Equity for 6 consecutive years, with -$31.5 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 156.35% to -$31.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$31.5 million through Dec 2025, down 156.35% year-over-year, with the annual reading at -$31.5 million for FY2025, 156.35% down from the prior year.
  • Common Equity hit -$31.5 million in Q4 2025 for Insight Molecular Diagnostics, down from -$9.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $106.6 million in Q1 2021 to a low of -$31.5 million in Q4 2025.
  • Historically, Common Equity has averaged $38.3 million across 5 years, with a median of $35.2 million in 2022.
  • Biggest five-year swings in Common Equity: skyrocketed 191.13% in 2021 and later plummeted 194.7% in 2025.
  • Year by year, Common Equity stood at $65.2 million in 2021, then plummeted by 47.42% to $34.3 million in 2022, then plummeted by 40.31% to $20.5 million in 2023, then tumbled by 159.97% to -$12.3 million in 2024, then crashed by 156.35% to -$31.5 million in 2025.
  • Business Quant data shows Common Equity for IMDX at -$31.5 million in Q4 2025, -$9.2 million in Q3 2025, and $1.1 million in Q2 2025.